Gossamer bio announces fourth quarter and full-year 2023 financial results and provides business update

San diego--(business wire)--gossamer bio, inc. (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah), today announced its financial results for the fourth quarter and year ended december 31, 2023, and provided a business update. “we were thrilled to enroll the first patient in the registrational prosera study last year, and we are pleased with the pace of site activati.
GOSS Ratings Summary
GOSS Quant Ranking